Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | KAT7 | O95251 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18850 | 1.00 | NR1H2 (0.51) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1184434 | 1.00 | NR1H2 (0.51) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL22168000 | 0.93 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL22168285 | 0.93 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16931340 | 0.91 | NR1H2 (0.49) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20541079 | 0.91 | NR1H2 (0.46) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31297386 | 0.91 | NR1H2 (0.49) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL30111484 | 0.91 | NR1H2 (0.46) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1944901 | 0.91 | NR1H2 (0.49) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL28942832 | 0.91 | NR1H2 (0.49) | NR1H2MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114349711-B | Synthesis method of (R) -1-Boc-3-hydroxymethyl piperazine | 四川依维欣医药科技有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-114349711-A | Synthesis method of (R) -1-Boc-3-hydroxymethyl piperazine | 四川恒康科技发展有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-118184657-A | PARP7 inhibitor and preparation method and application thereof | 成都先导药物开发股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20230348462-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348462-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-11-02 | — | — | US | disclosed |
| CN-114349711-B | Synthesis method of (R) -1-Boc-3-hydroxymethyl piperazine | 四川依维欣医药科技有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022115439-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022096361-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-05-12 | — | — | WO | disclosed |
| EP-3992191-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | Deutsches Krebsforschungszentrum (DE) | 2022-05-04 | — | — | EP | disclosed |
| CN-114349711-A | Synthesis method of (R) -1-Boc-3-hydroxymethyl piperazine | 四川恒康科技发展有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002012185-A1 | PROCESS FOR PREPARING 2,3-DIAMINOPROPANOLS AND SYNTHESIS OF OTHER COMPOUNDS USING 2,3-DIAMINOPROPANOLS | CHEMBIONEX CO., LTD. (KR) | 2002-02-14 | — | — | WO | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-0495750-A2 | Heterocyclic hydroxylamine | CIBA-GEIGY AG (CH) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | NR1H2 952/4885MEN1 3419/4885ALDH1A1 112/4885 |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | NR1H2 1095/4885MEN1 2216/4885ALDH1A1 1316/4885 |
| US-20230348462-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | NR1H2 2104/4885MEN1 2251/4885ALDH1A1 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.